Interaction between the FTO gene, body mass index and depression: meta-analysis of 13/701 individuals


Background
Depression and obesity are highly prevalent, and major impacts on public health frequently co-occur. Recently, we reported that having depression moderates the effect of the FTO gene, suggesting its implication in the association between depression and obesity.

Aims
To confirm these findings by investigating the FTO polymorphism rs9939609 in new cohorts, and subsequent in a meta-analysis.

Method
The sample consists of 6902 individuals with depression and 6799 controls from three replication cohorts and two original discovery cohorts. Linear regression models were performed to test for association between rs9939609 and body mass index (BMI), and for the interaction between rs9939609 and depression status for an effect on BMI. Fixed and random effects meta-analyses were performed using METASOFT.

Results
In the replication cohorts, we observed a significant interaction between FTO, BMI and depression with fixed effects meta-analysis (β = 0.12, P = 2.7 x 10^-5) and with the Han/Eskin random effects method (P = 1.4 x 10^-7) but not with traditional random effects (β = 0.1, P = 0.35). When combined with the discovery cohorts, random effects meta-analysis also supports the interaction (β = 0.12, P = 0.027) being highly significant based on the Han/Eskin model (P = 6.9 x 10^-5). On average, carriers of the risk allele who have depression have a 2.2% higher BMI for each risk allele, over and above the main effect of FTO.

Conclusions
This meta-analysis provides additional support for a significant interaction between FTO, depression and BMI, indicating that depression increases the effect of FTO on BMI. The findings provide a useful starting point in understanding the biological mechanism involved in the association between obesity and depression.

Declaration of interest
K.J.A., A.E.F. and P.M. have received consultancy fees and honoraria for participating in expert panels for pharmaceutical companies including GlaxoSmithKline (GSK). P.M. has received speaker’s fees from Pfizer. K.J.A. has been on the advisory board for Bristol-Myers Squibb and Otsuka Pharmaceutical and in addition received consultancy fees including payment for lectures and educational presentations. She was previously a member of other advisory boards, receiving consultancy fees and honoraria, and has received research grants from various companies including Lundbeck and GSK. F.H. is co-founder of the biotech company Holsboer Maschmeyer Neuro Chemie GmbH (NMNC GmbH) in Germany. W.M. is a member of the advisory boards and has received fees for speaking from Lilly and Lundbeck. M.P. is part of advisory boards for Eli Lilly and Lundbeck.© The Royal College of Psychiatrists 2017. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) licence.
In 2012, we reported the first study identifying an interaction effect between FTO genotype, depression and increased risk of obesity in two independent samples of patients with depression and psychiatrically healthy controls, in which the effect of FTO was increased in those individuals who had experienced depression.

In the current study, we first replicate the FTO rs9939609 depression interaction in 3 independent cohorts and then combine results with the 2 original cohorts for a total combined meta-analysis of 6992 patients with depression and 6799 psychiatrically healthy controls.

Method

Samples

This meta-analysis includes data from five different studies: Radiant, PsyCoLaus, GSK, MARS and NESDA/NTR.

Original cohorts

Extended Radiant

The depressive disorder sample included 2442 individuals sourced from several studies described in detail elsewhere: the Depression Case Control (DeCC) study, Depression Network (DeNT) study, and the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. The DeCC is a case-control study that recruited individuals from three UK sites (London, Cardiff and Birmingham). The DeNT sibling pair linkage study includes cases of recurrent unipolar depression collected at seven European sites and one US site. All participants in the DeCC and DeNT studies had experienced at least two episodes of major depression of at least moderate severity. The GENDEP study includes individuals with one or more episodes of depression of at least moderate severity recruited from nine European centres.

Diagnoses of major depressive disorder (MDD) was ascertained using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview in all three studies. The control sample comprised 809 controls from the UK who were screened for lifetime absence of any psychiatric disorder using a modified version of the Past History Schedule. All cases and controls were of White European ancestry.

PsyCoLaus study

The PsyCoLaus study focused on psychiatric symptoms in a population-based cohort randomly selected from the list of residents of the city of Lausanne (Switzerland) and originally assessed for cardiovascular risk factors (GoLaus study). All 35- to 66-year-old individuals of the CoLaus sample were invited to participate in the psychiatric evaluation for the PsyCoLaus substudy (see Firman et al for a detailed description). The PsyCoLaus sample included 1286 individuals who fulfilled lifetime criteria for MDD according to DSM-IV based on assessment using the Diagnostic Interview for Genetic Studies (DIGS). The control sample included 1698 PsyCoLaus participants who had never fulfilled criteria for MDD. The PsyCoLaus study has been described in more detail elsewhere.

Replication cohorts

GSK study

Participants from this study were recruited at the Max Planck Institute for Psychiatry in Munich, Germany, and at two satellite recruiting hospitals in the Munich area (BKII Augsburg and Klinikum Ingolstadt). A total of 821 White European individuals diagnosed with recurrent MDD and 856 White European age- and gender-matched unaffected controls were included in the meta-analysis. All patients with depression were evaluated using the SCAN interview and were included in the study if they had experienced at least two moderate to severe depression episodes according to DSM-IV. Controls were excluded if anxiety and mood disorders were present using the Composite International Diagnostic Screener (CIDS). The study has been described in detail elsewhere.

MARS study

The Munich Antidepressant Response Signature (MARS) project at the Max Planck Institute of Psychiatry in Munich, Germany (www.mars-depression.de) is a naturalistic clinical study of in-patients with a major depressive episode. Individuals with a DSM-IV diagnosis of major depressive episode or recurrent depression (n = 575) were included in this meta-analysis. Five hundred and forty-one controls randomly selected from Munich community registries and screened for the absence of a lifetime history of DSM-IV Axis I disorders were included in the analyses. All patients and controls were of White European origin. Study details have been described previously.

NESD/BTR studies

This sample is part of the Netherlands Study of Depression and Anxiety (NESDA) and the Netherlands Twin Register (NTR). NESDA is a naturalistic multicentre and longitudinal cohort study designed to examine the course and consequences of individuals with depressive and anxiety disorders. Recruitment of participants was from the general population, general practices and mental health organisations.

The NTR project, in 1994, started collecting longitudinal data from twins and their families to create a resource for genetic studies on health, lifestyle and personality.

In both cohorts, similar inclusion and exclusion criteria were used to select MDD cases. The Composite Interview Diagnostic Interview (CIDI) was used to diagnose depressive disorders according to the DSM-IV criteria. The control group had no lifetime diagnosis of depression or anxiety disorders. Controls were partly confirmed by the absence of lifetime diagnoses of psychiatric disorders, and partly by repeated measures of low genetic liability for MDD (determined by factor score derived from longitudinal measures of neuroticism, anxiety and depressive symptoms).

Participants included in these studies were required to report western European ancestry. These studies have been previously described in more detail.

The case sample comprised 1636 individuals from NESDA and 132 from NTR. The controls were mainly from NTR (n = 2470) with 424 additional controls from NESDA.

Phenotypic data

In all studies, BMI was defined as weight in kilograms divided by height in metres squared (kg/m²). In Radiant, self-reported height and weight were obtained during the SCAN interview for cases and telephone interview for controls. The reliability of self-report of height and weight was assessed in the GENDEP data-set (n = 811) where we had also measured height and weight. The correlations for measured v. self-reported height, weight and BMI were 0.97, 0.95 and 0.95, respectively.

In the PsyCoLaus sample, weight and height were measured at the outpatient clinic at the Centre Hospitalier Universitaire Vaudois (CHUV). In the GSK and MARS studies, anthropometric measures for patients and controls were taken at the Max Planck Institute for Psychiatry in Munich, Germany.
Institute and associated study sites by trained technicians and study nurses.\footnote{19,20,21}

Weight and height were measured by medical examination at the study clinic during the visit for NESDA,\footnote{22} and during the home visit after blood sampling for NTR.\footnote{23}

In all studies the distribution of BMI was positively skewed. We therefore transformed the data to $\log_{10}(\text{BMI})$ to achieve a closer approximation to normal distribution.

### Genotyping

The samples from the different studies were all genotyped with SNP arrays. If rs9939609 was not genotyped directly on the array, genotypes were imputed and best guess genotypes were used to perform the statistical analyses. For the Radiant study, we report results from a larger sample than previously reported for the UK subsample ($n = 2174$).\footnote{24} A thorough description of all genotyping and imputation is described for each study in more detail elsewhere.\footnote{25,26,27}

**Inclusion criteria**

As common inclusion criteria, we looked for studies with information available on a lifetime DSM-IV diagnosis of MDD, BMI and genotype data for the rs9939609 FTO polymorphism. Homogeneous ethnicity (White European) was also required for each study to be included in the meta-analysis to reduce the risk of population stratification. Demographic and clinical characteristics of the participants from the five studies included in the meta-analysis are summarised in Table 1.

### Statistical analyses

In each study, linear regression models were performed to test for association between rs9939609 polymorphism and $\log_{10}($BMI) assuming an additive genetic model. Models were tested separately in the cases and controls and in the combined sample. We then tested the interaction effect between rs9939609 variant and depression status on $\log_{10}($BMI). Gender and age were included as covariates in the regression analyses. Genotype-based principal components were used to control for possible population stratification within each study. Standardised beta coefficients were obtained in each study to allow direct comparison between studies. Statistical analyses were performed using PLINK v1.07.\footnote{28}

**Meta-analyses of main association effects**

Fixed effects meta-analyses of the association between rs9939609 variant and $\log_{10}($BMI) were performed in the whole sample and in cases and controls separately, using PLINK v1.07.\footnote{28}

Heterogeneity across studies was assessed using Cochran's $Q$ statistic and $I^2$ heterogeneity index.

**Meta-analysis of the interaction effect**

Fixed effects and random effects meta-analyses based on inverse-variance-weighted effect size of the interaction effects were performed using METAOF.\footnote{29} (http://genetics.cs.ucl.ac.uk/meta/index.html). Heterogeneity across studies was assessed using Cochran's $Q$ statistic and $I^2$ heterogeneity index.

### Results

#### Main effects of the association between FTO and BMI

**Original cohorts: Extended Radiant and PsyCoLaus**

In Radiant, as previously reported in a subset of the same data,\footnote{19} there was a significant association, although strengthened in significance here, between the rs9939609 A variant and $\log_{10}($BMI) ($\beta = 0.08, P = 0.001$ in the whole sample.

Linear regression analysis in PsyCoLaus also showed that the rs9939609 A variant was significantly associated with $\log_{10}($BMI) ($\beta = 0.07, P = 0.006$).

Moreover, in both studies the association was strengthened when analysing the cases alone (Radiant: $\beta = 0.12, P = 6.15 \times 10^{-5}$; PsyCoLaus: $\beta = 0.72, P = 8.52 \times 10^{-4}$). The analyses in the control groups alone showed no significant association with $\log_{10}($BMI) (Table 2).

**Replication cohorts: GSK, MARS and NESDA/NTR**

In the GSK and MARS studies, there were no statistically significant associations between the FTO rs9939609 A variant and $\log_{10}($BMI) (Table 2). In NESDA/NTR, the rs9939609 A allele was associated with $\log_{10}($BMI) in the whole sample ($\beta = 0.09, P = 1.24 \times 10^{-5}$) and showed a stronger effect in the depression group alone than in the combined sample ($\beta = 0.2, P = 2.26 \times 10^{-4}$), whereas the association in controls was not significant (Table 2).

In all studies, depression status, gender, age and principal components were included as covariates when the analyses were performed in the combined sample; gender, age and principal components were included when cases and controls were analysed separately. The results for the association analyses between the rs9939609 polymorphism and $\log_{10}($BMI) in the whole sample, and in cases and controls separately, for each individual study are shown in Table 2.

We also explored the association between FTO gene and depression in all the studies and found no association between the rs9939609 A risk variant and depression (data not shown).

### Table 1: Demographic and Clinical Characteristics of the Participants from the Studies Included in the Meta-analysis

<table>
<thead>
<tr>
<th></th>
<th>Radiant Cases</th>
<th>Radiant Controls</th>
<th>PsyCoLaus Cases</th>
<th>PsyCoLaus Controls</th>
<th>GSK Cases</th>
<th>GSK Controls</th>
<th>MARS Cases</th>
<th>MARS Controls</th>
<th>NESDA/NTR Cases</th>
<th>NESDA/NTR Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size, n</td>
<td>2442</td>
<td>809</td>
<td>1296</td>
<td>1698</td>
<td>821</td>
<td>856</td>
<td>575</td>
<td>541</td>
<td>1768</td>
<td>2895</td>
</tr>
<tr>
<td>Gender, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>30.3</td>
<td>38.7</td>
<td>33.49</td>
<td>53.36</td>
<td>33.74</td>
<td>32.48</td>
<td>47.13</td>
<td>44.92</td>
<td>31.4</td>
<td>38.7</td>
</tr>
<tr>
<td>Female</td>
<td>69.7</td>
<td>61.3</td>
<td>66.51</td>
<td>46.64</td>
<td>66.26</td>
<td>67.52</td>
<td>52.87</td>
<td>55.08</td>
<td>68.6</td>
<td>61.3</td>
</tr>
<tr>
<td>Mean age (s.d.), years</td>
<td>45.25</td>
<td>39.90</td>
<td>49.69</td>
<td>50.59</td>
<td>50.94</td>
<td>51.92</td>
<td>48.09</td>
<td>47.42</td>
<td>42.68</td>
<td>42.83</td>
</tr>
<tr>
<td></td>
<td>(4.32)</td>
<td>(4.31)</td>
<td>(3.84)</td>
<td>(3.80)</td>
<td>(4.89)</td>
<td>(4.08)</td>
<td>(4.52)</td>
<td>(4.72)</td>
<td>(5.13)</td>
<td>(4.00)</td>
</tr>
</tbody>
</table>

GSK, GlaxoSmithKline study; MARS, Munich Antidepressant Response Signature project; NESDA/NTR, Netherlands Study of Depression and Anxiety/Netherlands Twin Register.
### Meta-analyses of the main effects of the association between FTO and BMI

Fixed effects meta-analysis supports a significant association between rs939609 polymorphism and log_{10}(BMI) in the whole sample and in cases (whole sample: \( \beta = 0.07, P = 1.29 \times 10^{-12}; \) cases: \( \beta = 0.12, P = 6.92 \times 10^{-13} \)). There was no association between rs939609 and log_{10}(BMI) in controls (\( \beta = 0.02, P = 0.15 \)).

No significant heterogeneity was detected among studies (whole sample: \( Q = 0.7, I^2 = 0; \) cases: \( Q > 0.05, I^2 = 56.88; \) controls: \( Q = 0.21, I^2 = 31.43 \)). The results for the fixed effects meta-analyses in each group are shown in Table 2.

### Interaction between FTO, BMI and depression

**Original studies:** Extended Radiant and PsyCoLaus

In the analysis of updated data from the original studies, we confirmed the significant interaction effect on log_{10}(BMI) between rs939609 genotype and depression that we had previously published (Radiant: \( \beta = 0.18, P = 0.002; \) PsyCoLaus: \( \beta = 0.12, P = 0.034 \) (Table 3). The \( P \)-value for the interaction results in the Radiant extended sample is lower than previously reported (\( P = 0.005 \)).

Replication studies: GSK, MARS and NESDA/NTR

There was also no significant interaction effect in GSK (\( \beta = -0.09, P = 0.168 \) (Table 3). The interaction effect in MARS was consistent with NESDA/NTR (\( \beta = 0.26 \), but was not significant (\( P = 0.083 \), likely reflecting the smaller sample size in MARS. The NESDA/NTR studies showed a significant interaction between rs939609 genotype and depression status in relation to log_{10}(BMI) (NESDA/NTR: \( \beta = 0.19, P = 3.22 \times 10^{-7} \), replicating our previous findings.

Meta-analysis of the interaction effect between rs939609 and depression in the three replication cohorts was also consistent with our earlier finding. In the fixed effects analysis there was

### Table 2: Association results between the rs939609 polymorphism and standardised log_{10}(BMI) and fixed effects meta-analyses in the whole sample and in cases and controls separately

<table>
<thead>
<tr>
<th>Study</th>
<th>Whole sample</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( n )</td>
<td>( \beta )</td>
<td>s.e.</td>
</tr>
<tr>
<td>Radiant</td>
<td>3251</td>
<td>0.08</td>
<td>0.02</td>
</tr>
<tr>
<td>PsyCoLaus</td>
<td>2994</td>
<td>0.07</td>
<td>0.02</td>
</tr>
<tr>
<td>GSK</td>
<td>1677</td>
<td>0.04</td>
<td>0.03</td>
</tr>
<tr>
<td>MARS</td>
<td>1116</td>
<td>0.06</td>
<td>0.04</td>
</tr>
<tr>
<td>NESDA/NTR</td>
<td>4663</td>
<td>0.09</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Meta-analysis: fixed effects

\[ 13,701 \quad 0.07 \quad 0.01 \quad 1.3 \times 10^{-2} \quad 0.12 \quad 0.02 \quad 6.9 \times 10^{-11} \quad 0.02 \quad 0.01 \quad 0.15 \]

BMI, body mass index; GSK, GlaxoSmithKline study; MARS, Munich Antidepressant Response Signature project; NESDA/NTR, Netherlands Study of Depression and Anxiety/Netherlands Twin Register.

### Table 3: Interaction results between rs939609 risk allele and depression on log_{10}(BMI) in the five independent studies and fixed effects, random effects and Han/Esken model meta-analyses

<table>
<thead>
<tr>
<th>Study</th>
<th>( n )</th>
<th>( \beta )</th>
<th>s.e.</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiant</td>
<td>3251</td>
<td>0.18</td>
<td>0.06</td>
<td>0.002</td>
</tr>
<tr>
<td>PsyCoLaus</td>
<td>2994</td>
<td>0.12</td>
<td>0.05</td>
<td>0.034</td>
</tr>
<tr>
<td>GSK</td>
<td>1677</td>
<td>-0.09</td>
<td>0.07</td>
<td>0.168</td>
</tr>
<tr>
<td>MARS</td>
<td>1116</td>
<td>0.26</td>
<td>0.15</td>
<td>0.083</td>
</tr>
<tr>
<td>NESDA/NTR</td>
<td>4663</td>
<td>0.19</td>
<td>0.04</td>
<td>3.2 \times 10^{-6}</td>
</tr>
</tbody>
</table>

Meta-analysis

Fixed effects

<table>
<thead>
<tr>
<th>Replication studies</th>
<th>( n )</th>
<th>( \beta )</th>
<th>s.e.</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>All studies</td>
<td>13701</td>
<td>0.13</td>
<td>0.03</td>
<td>3.1 \times 10^{-7}</td>
</tr>
<tr>
<td>All studies (no GSK)</td>
<td>12024</td>
<td>0.17</td>
<td>0.03</td>
<td>1.1 \times 10^{-9}</td>
</tr>
</tbody>
</table>

Random effects

<table>
<thead>
<tr>
<th>Replication studies</th>
<th>( n )</th>
<th>( \beta )</th>
<th>s.e.</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>All studies</td>
<td>13701</td>
<td>0.12</td>
<td>0.05</td>
<td>0.02</td>
</tr>
<tr>
<td>All studies (no GSK)</td>
<td>12024</td>
<td>0.17</td>
<td>0.03</td>
<td>1.1 \times 10^{-9}</td>
</tr>
</tbody>
</table>

Han/Esken model

<table>
<thead>
<tr>
<th>Replication studies</th>
<th>( n )</th>
<th>( \beta )</th>
<th>s.e.</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>All studies</td>
<td>13701</td>
<td>0.12</td>
<td>0.05</td>
<td>6.9 \times 10^{-8}</td>
</tr>
<tr>
<td>All studies (no GSK)</td>
<td>12024</td>
<td>0.17</td>
<td>0.03</td>
<td>1.7 \times 10^{-9}</td>
</tr>
</tbody>
</table>

Meta-analysis

<table>
<thead>
<tr>
<th>Replication studies</th>
<th>( n )</th>
<th>( \beta )</th>
<th>s.e.</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>All studies</td>
<td>13701</td>
<td>85.3(^{a})</td>
<td>13.61(^{a})</td>
<td>0.001(^{a})</td>
</tr>
<tr>
<td>All studies (no GSK)</td>
<td>12024</td>
<td>72.6(^{c})</td>
<td>14.60(^{c})</td>
<td>0.006(^{c})</td>
</tr>
</tbody>
</table>

BMI, body mass index; GSK, GlaxoSmithKline study; MARS, Munich Antidepressant Response Signature project; NESDA/NTR, Netherlands Study of Depression and Anxiety/Netherlands Twin Register.

a: Replication studies GSK, MARS and NESDA/NTR.
b: \( P \)-statistic.
c: \( Q \)-statistic.
d: \( P \)-value of \( Q \).
directional consistency and a significant association, with a greater increase in BMI for individuals with depression carrying rs9939609 alleles ($\beta = 0.12$, $P = 2.72 \times 10^{-5}$). Owing to the opposite but non-significant interaction effect observed in GSK, a traditional random effects meta-analysis was not significant ($\beta = 0.10$, $P = 0.35$). However, the Han/Emkin random effects model, $^{19}$ optimized to detect an effect in the presence of heterogeneity, was able to detect the interaction effect ($P = 1.35 \times 10^{-7}$) (Table 3).

### Five study meta-analysis of the interaction effect

Fixed effects meta-analysis in all five studies further confirmed the interaction between FTO, BMI and depression ($\beta = 0.13$, $P = 3.1 \times 10^{-7}$) (Table 3). A forest plot showing the interaction effect in each study as well as the fixed effects meta-analysis is shown in Fig. 1. The effect corresponds to an additional increase of 2.2% in BMI for subjects with depression for each risk allele, over and above the main effect of FTO. This translates to a 1.76 kg weight increase in an individual whose height and weight were 180 cm and 8 kg. Similar to meta-analysis in the three new cohorts, traditional random effects meta-analysis was only nominally significant ($\beta = 0.12$, $P = 0.02$), but highly significant based on the Han/Emkin model ($P = 6.89 \times 10^{-4}$) (Table 3).

### Heterogeneity and sensitivity analyses

Both the three-study replication meta-analysis and the full meta-analysis showed significant heterogeneity among studies, using both Cochran's $Q$ statistic ($Q_{1,	ext{norm}} = 0.001$, $Q_{2,	ext{norm}} = 0.006$) and $I^2$ (3-way index 85.3%, 5-way index 72.6%). GSK accounted for the full extent of the heterogeneity. In sensitivity analyses of both the replication and full meta-analysis, removing GSK increased the significance of both fixed effects and random effects associations and eliminated all evidence of heterogeneity (Table 3).

### Discussion

The main effect meta-analysis showed a significant association between FTO and BMI in the whole sample. This association was attributed to the case group alone, with no association found in controls, replicating our previous findings. $^{19}$

In the Radiant, GSK and NDEA/NTR studies, patients with depression had higher BMI than controls. This could be attributable to a side-effect of antidepressant treatment or because individuals with depression are less physically active and/or have an increased food intake. In MARS, BMI in controls was higher than in patients with depression, and this could be because this study includes patients with untreated, first-episode depression. In the PsyCoLaus sample, BMI was not different between cases and controls. These differences possibly reflect the fact that PsyCoLaus participants were recruited from the community and were an arguably less severely affected group (18% were experiencing a current depressive episode and 82% were in remission), where only one episode was required for inclusion and only 37.5% of cases had ever received treatment with antidepressants.

In addition to this, the control samples were screened to have no history of psychiatric disorders. Previous studies investigating BMI, obesity and FTO have not taken this into account and it could further explain why there is no association observed in the control samples.

Another plausible explanation for the BMI differences across studies could be the clinical heterogeneity of depression. Evidence suggests that metabolic dysregulation may be more involved in one subtype of depression (atypical) than in another (melancholic). $^{40}$ Recently, it has been shown that obesity and increased appetite are more prevalent in atypical depression, whereas rates of obesity are similar or even lower compared with controls in melancholic (typical) depression. $^{40,41}$ Therefore, when considering the overall depression diagnosis these differential effects are blurred.

Unfortunately, we could not include medication as a covariate in the analyses as this information was not available for all the studies. Therefore, we cannot exclude the possibility that the FTO effect that we have found is at least partly reflecting an increased susceptibility to the weight-inducing effects of medications. We also cannot exclude the possibility that psychiatric conditions that are frequently comorbid with depression play a part in modulating the effect of FTO.

The involvement of overlapping physiological mechanisms and shared genes between depression and obesity could support the hypothesis that the two disorders have shared genetic vulnerability. $^{5}$ In 2010, a systematic review and meta-analysis on the longitudinal relationship between depression, overweight and obesity confirmed a bidirectional association between depression and obesity. $^{4}$ Several lines of evidence support the possibility of a biological pathway. Metabolic, immune-inflammatory and hypothalamic-pituitary-adrenal (HPA) axis dysregulations could be mediators of the reported association as they have a role in both depression and obesity. $^{10}$

Psychological factors such as body dissatisfaction, low self-esteem, stigmatization and eating patterns should also be considered in addition to the biological mechanisms and could further contribute to the observed association between depression and obesity. $^{12,44}$ Reduced physical activity, sedentary lifestyle and/or unhealthy dietary choices as well as antidepressant treatment could be additional risk factors that induce weight gain in individuals with depression who are genetically predisposed to the disorder.

Unfortunately, measures of important confounding factors such as smoking, alcohol consumption or socioeconomic status, which might influence the association between higher BMI and MDD, were not available for all the studies.

### Gene: FTO

<table>
<thead>
<tr>
<th>P-value</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.163</td>
<td>1. GSK</td>
</tr>
<tr>
<td>0.0338</td>
<td>2. PsyCoLaus</td>
</tr>
<tr>
<td>0.0826</td>
<td>3. MARS</td>
</tr>
<tr>
<td>2.79 x 10^{-4}</td>
<td>NDEA/NTR</td>
</tr>
<tr>
<td>0.0021</td>
<td>5. Radiant</td>
</tr>
</tbody>
</table>

### RE summary

![Forest plot showing interactions between FTO, depression and body mass index.](image)

GSK, GlaxoSmithKline study; MARS, Munich Antidepressant Response Signature project; NDEA/NTR, Netherlands Study of Depression and Anxiety/Netherlands Twin Register; RE, risk estimate.

For more details, please refer to the original publication.
The results from the meta-analysis of the interaction effect suggest a genetic mechanism by which individuals who have depression are at increased risk for obesity. Our results demonstrate that depression enhances the effect of FTO variants on BMI, such that individuals with depression have an additional 2.2% increase in BMI for each one standard deviation increase in FTO risk allele (A) compared with psychiatrically healthy control.

Limitations and conclusions

The main limitation of this study is that the inclusion criteria for participants, study design, recruitment, and sample composition vary across the studies. This could explain the significant heterogeneity found between studies.

To our knowledge this is the largest and most comprehensive study and meta-analysis investigating the interaction between FTO, BMI and depression concurrently. The overall interaction meta-analysis results suggest that having depression moderates the effect of FTO on BMI, such that the BMI-increasing effect is significantly enlarged. This meta-analysis demonstrates a modest but a consistent effect of the interaction between FTO, depression and BMI.

Although our analyses cannot infer causality or directionality about the relationship between obesity and depression, this study provides additional evidence that shared genetic factors between depression and obesity do exist. Furthermore, it is evident that FTO gene, BMI and depression influence brain structure.17,18 Altogether, our results indicate that depression-related alterations in key biological processes may interact with the FTO risk allele to increase BMI or obesity risk. Future studies that include samples followed longitudinally will be crucial to better understand the nature and direction of this association.

Overall, our findings provide evidence that FTO is involved in the association between obesity and depression. Although FTO genotyping has modest implications for predicting which patients with depression are at risk of BMI-related disorders, the findings provide a useful starting point in understanding the biological mechanisms involved in the association between obesity and depression. The identification of such mechanisms should in turn lead to better understanding of the development of comorbid states and eventually contribute to prevention of obesity-related disorders that are currently overrepresented among patients with depression.2

Funding

This study was funded by the Medical Research Council, UK, and GlaxoSmithKline (20051042). The GENQUP study was funded by a European Commission Framework 6 grant, EC Contract Ref.: LSHTM-CT-2003-504028. M.R. was supported by a fellowship from the Marie Curie Research Grants Scheme (PITN-242239). J.R. was supported by a fellowship from the Wellcome Trust (086833). K.J.A. holds an Alberta Centennial Addictions and Mental Health Research Chair funded by the Government of Alberta. This work was funded in part by the National Institutes for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King’s College London. This article presents independent research in part funded by the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The Caerus/Phycalus was funded by four grants from the Swiss National Science Foundation (153499, 155090, 150208, 150210), the Faculty of Biology and Medicine of Lausanne and two grants from GlaxoSmithKline Clinical Research. The MAAP project was funded by the Max Planck Society and in part by a research grant from the German Federal Ministry for Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN, 2 and NGFN-Plus, HQ 01G05018) and by the BMBF Programme "Molekular Diagnostik: Validierung von Biomarkern für Diagnose und Outcome in Major Depression" (03158133). Netherlands Twin Registry and Netherlands Study of Depression and Anxiety (NESDA) funding was obtained from the Netherlands Organization for Scientific Research (NWO) and Magnus Wijsman grants 919.00.032, Spinoza 2004-64-441492, Government Programme of the Netherlands Organisation for Health Research and Development (ZonMW 1000-4002), Center for Medical Systems Biology (CSB), NWO Genomics, Genomic influences on stability and change in psychopathology from childhood to young adulthood (JanM/MW 9.10-002), NWO/Balgos/WK (NG.MW.0018.006), BrainImaging and Biomolecular Resources Research Infrastructure (BMBRRI-NL, 184.031.010), VU University for the Health and Care Research (EMGO+i) and Neuroscience Campus Amsterdam (NCA), and the European Science Council (SSC Advanced, 230038). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GA IN) of the Foundation for the National Institutes of Health, Rutgers University Cell and DNA Repository (NMHI U24 MO04547-08), the Arteri Institute, South Falls, South Dakota, USA, and the Western Institute of Health (NIH RO1 HD45971-01A1, MH081502), General Opportunity grants TR2C M009953 and TR2C M009999.

Acknowledgements

The authors thank those who agreed to participate in the studies and the many colleagues who contributed to collection and phenotypic characterisation of the clinical samples, to genotyping and to statistical analyses.

Margaritha Rivera, PhD, Department of Biochemistry and Molecular Biology I and Institute of Neurosciences, Center for Biomedical Research, University of Granada, Granada, Spain, and MRC Social Genetic and Developmental Psychiatry Institute Centre for Research and Training in Psychiatry, Psychology, & Neurosciences, King’s College London, UK. Adam E. Locke, PhD, Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, USA; Tanguy Corre, PhD, Department of Medical Genetics, University of Geneva, Switzerland, and Institute of Bioinformatics, Lausanne, Switzerland, Darlina Czamara, PhD, Christiane Wollf, PhD, Max Planck Institute of Psychiatry, Munich, Germany, Ana Cling-Lopez, Department of Psychiatry, School of Medicine, University of Granada, and Institute of Neurosciences Federico Oliber, Instituto de Investigación Biomédica, University of Granada, Spain; Yuri Milaneschi, PhD, Department of Psychiatry and EMOG Institute for Health and Care Research, VU University Medical Center/UGG in Geest, Amsterdam, The Netherlands; Stefan Kliether, MD, Max Planck Institute of Psychiatry, Munich, Germany, Sera Cohen-Woods, PhD, School of Psychology, Flinders University, Adelaide, South Australia, Australia; Michael Rudolf, MD, PhD, MRC Social Genetic and Developmental Psychiatry Institute Centre for Research and Training in Psychiatry, Psychology, & Neurosciences, King’s College London, UK. Margaret De Stavola, PhD, Department of Psychiatry, University of Alberta, Alberta, Canada, Sven Bergmann, PhD, Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland, and Institute of Bioinformatics, Lausanne, Switzerland, Donnet L. Boomsma, PhD, Department of Biological Psychology, VU University Amsterdam, The Netherlands; Nick Craddock, MD, PhD, MRC Neurogenetics Unit, University of Oxford, Oxford, UK; Zoltan Kutalik, PhD, Department of Medical Genetics, University of Lausanne, Lausanne, and Swiss Institute of Bioinformatics, Lausanne, Switzerland, Susanne Lucae, MD, PhD, Max Planck Institute of Psychiatry, Munich, Germany, Wolfgang Maier, MD, Department of Psychiatry, University of Bonn, Bonn, Germany, Ole Mors, MD, PhD, Research Department P, Aarhus University Hospital, Risskov, Denmark, Bertram Müller-Mryn-Sch, MD, Max Planck Institute of Psychiatry, Munich, Germany, Michael S. Owen, MB, FRCS, MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, UK; Brenda W. J. H. Fornaris, PhD, Department of Neuroscience and EMOG Institute for Health and Care Research, VU University Medical Center/UGG in Geest, Amsterdam, The Netherlands; Martin Preissl, MD, Department of Psychiatry, Lausanne University Hospital, 1008 Lausanne, Switzerland; John Rice, MD, Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA; Marcelia Riedel, PhD, Central Institute of Mental Health, Mannheim, Germany; Federica Pugliese, GlaxoSmithKline Research and Development, Verona, Italy; Rudolf Uher, MD, PhD, MRC Social Genetic and Developmental Psychiatry Institute Centre for Research and Training in Psychiatry, Psychology, & Neurosciences, King’s College London, UK; and Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada; Peter Vollenweider, MD, PhD, Gerard Wuebl, MD, PhD, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, UK, and Institute of Medical and Molecular Genetics, School of Medicine, King’s College London, UK; Gerardine Breun, MD, PhD, Peter McCallum, MB, PhD, MRC Social Genetic and Developmental Psychiatry Institute Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, UK, and Department of Medical and Molecular Genetics, School of Medicine, King’s College London, UK.

Correspondence: Margaritha Rivera, PhD, Center for Biomedical Research, University of Granada, Avda del Conocimiento s/n, Armilla, Granada 18016, Spain. Email: margaritha.rivera@usal.es

First received 19 Feb 2016, final revision 12 Jan 2017, accepted 13 Mar 2017

References


Interaction between the *FTO* gene, body mass index and depression: meta-analysis of 13701 individuals


BJP published online June 22, 2017 Access the most recent version at DOI: 10.1192/bjp.bp.116.183475